Absence of functional EpoR expression in human tumor cell lines
Authors:
- 27 May 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 115 (21) , 4254-4263
Abstract
Certain oncology trials showed worse clinical outcomes in the erythropoiesis-stimulating agent (ESA) arm. A potential explanation was that ESA-activated erythropoietin (Epo) receptors (EpoRs) promoted tumor cell growth. Although there were supportive data from preclinical studies, those findings often used invalidated reagents and methodologies and were in conflict with other studies. Here, we further investigate the expression and function of EpoR in tumor cell lines. EpoR mRNA levels in 209 human cell lines representing 16 tumor types were low compared with ESA-responsive positive controls. EpoR protein production was evaluated in a subset of 66 cell lines using a novel anti-EpoR antibody. EpoR+ control cells had an estimated 10 000 to 100 000 EpoR dimers/cell. In contrast, 54 of 61 lines had EpoR protein levels lower than 100 dimers/cell. Cell lines with the highest EpoR protein levels (400-3200 dimers/cell) were studied further, and, although one line, NCI-H661, bound detectable levels of [125I]–recombinant human Epo (rHuEpo), none showed evidence of ESA-induced EpoR activation. There was no increased phosphorylation of STAT5, AKT, ERK, or S6RP with rHuEpo. In addition, EpoR knockdown with siRNAs did not affect viability in 2 cell lines previously reported to express functional EpoR (A2780 and SK-OV-3). These results conflict with the hypothesis that EpoR is functionally expressed in tumors.Keywords
This publication has 41 references indexed in Scilit:
- Erythroid-Stimulating Agents in Cancer Therapy: Potential Dangers and Biologic MechanismsJournal of Clinical Oncology, 2009
- Evaluating Erythropoietin-Associated Tumor Progression Using Archival Tissues from a Phase III Clinical TrialStem Cells, 2009
- RNA Interference-Mediated Inhibition of Erythropoietin Receptor Expression Suppresses Tumor Growth and Invasiveness in A2780 Human Ovarian Carcinoma CellsThe American Journal of Pathology, 2009
- Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cellsBritish Journal of Cancer, 2008
- Optimization and Utilization of the SureFire Phospho-STAT5 Assay for a Cell-Based Screening CampaignASSAY and Drug Development Technologies, 2008
- Lack of functional erythropoietin receptors of cancer cell linesInternational Journal of Cancer, 2007
- Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel‐resistant phenotypeInternational Journal of Cancer, 2007
- Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cellsInternational Journal of Cancer, 2007
- Hypoxia induces the expression of the pro-apoptotic gene BNIP3Cell Death & Differentiation, 2001
- Erythropoietin receptor expression on human bone marrow erythroid precursor cells by a newly-devised quantitative flow-cytometric assayBritish Journal of Haematology, 1997